Alumis's Psoriasis Drug Surpasses Expectations in Late-Stage Trials
Alumis's experimental drug envudeucitinib achieved significant success in late-stage trials for plaque psoriasis, showing superior results to Amgen's Otezla. The positive outcome led to a substantial premarket stock increase for Alumis, with plans for U.S. regulatory submission in 2026.
Insights:
Alumis Inc announced on January 6 that its experimental oral drug, envudeucitinib, has met the primary endpoints in two late-stage clinical trials aimed at treating moderate-to-severe plaque psoriasis. The trials revealed that 65% of patients experienced a 90% or greater improvement in their symptoms, while over 40% achieved complete clearance after 24 weeks of treatment. These results not only surpassed the performance of a placebo but also outperformed Amgen Inc's approved oral drug, Otezla.
The announcement has catalyzed a remarkable surge in Alumis's stock, which soared over 90% in premarket trading, reflecting strong market confidence in the drug's commercial potential. Envudeucitinib works by inhibiting TYK2, a protein that triggers immune signals linked to inflammation, thereby addressing the underlying immune dysfunction associated with psoriasis.
